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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effectiveness and safety of various treatment strategies in patients with grommets who developed ear discharge.
B A C K G R O U N D
Description of the condition
The insertion of grommets (also known as ventilation tubes or
tympanostomy tubes) is one of the most common surgical proce-
dures performed in children worldwide, with around 25,000 pro-
cedures performed in the UK (Position Paper ENT UK 2009),
and almost 700,000 in the United States each year (Cullen 2009).
The two main indications for this operation include restoration of
hearing in children with persistent bilateral otitis media with ef-
fusion (also called ’glue ear’) and prevention of further middle ear
infections in children suffering from recurrent acute otitis media.
Ear discharge (also called otorrhoea) is a common sequela in pa-
tients with grommets; it is generally considered to be a symptom of
amiddle ear infectionwhereby fluid that has built up in themiddle
ear drains through the grommet into the ear canal. Ear discharge
associated with grommets is generally divided into early postop-
erative versus late ear discharge based on the time at which the
condition occurs (with early postoperative ear discharge usually
defined as ear discharge occurring within two weeks after insertion
of the grommets). Estimations of the proportion of patients with
grommets developing ear discharge range from 25%, in a meta-
analysis of mainly observational studies, to 75% in a randomised
controlled trial (Ah-Tye 2001; Kay 2001; van Dongen 2013). Ear
discharge is most unpleasant, as it can smell bad, while the un-
derlying middle ear infection may cause general illness, fever and
pain. Ear discharge persisting for three days or more has a negative
impact on children’s quality of life (Rosenfeld 2000). Although
most episodes of ear discharge in patients with grommets last days
to weeks, some patients develop chronic ear discharge, which may
be associated with considerable morbidity and hearing loss.
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Description of the intervention
Various interventions and combinations of interventions are used
to treat ear discharge in patients with grommets. Broad-spectrum
oral antibiotics, topical antibiotics with or without topical cor-
ticosteroids and initial observation are the most commonly used
in daily clinical practice. Other (additional) interventions include
suction of the discharging ear, saline rinsing and systemic or top-
ical corticosteroids.
Several studies have shown that ENT surgeons tend to pre-
scribe eardrops containing antibiotics with or without corticos-
teroids, while general practitioners (GPs) and emergencymedicine
physicians frequently prescribe oral antibiotics to these patients
(Badalyan 2013; Bickerton 1988; Robb 1991). The fear of oto-
toxicity appears to be an important reason for physicians to re-
frain from treatment with topical antibiotics (Bickerton 1988).
Aminoglycosides are considered potentially ototoxic, although the
available evidence on this topic is of rather poor quality and oto-
toxicity is considered to be a rare complication given its frequent
use (Pappas 2006; Phillips 2007). The use of chloramphenicol
and polymyxin B eardrops has been associated with hair cell dam-
age (Pappas 2006). Quinolone eardrops are considered to be non-
ototoxic and are therefore frequently prescribed (Bagger-Sjöbäck
1992; Pappas 2006).
In this review we will assess the effectiveness and safety of the var-
ious interventions for ear discharge in patients with grommets.
Treatment strategies for (the prevention of ) ear discharge occur-
ring shortly after the insertion of grommets (also called early post-
operative ear discharge) are beyond the scope of this review and
are addressed in a separate Cochrane review (Syed 2013).
How the intervention might work
Bacterial infection of the middle ear is thought to be the pre-
dominant cause of ear discharge. The bacteria involved in ear dis-
charge in patients with grommets include the typical acute oti-
tis media pathogens, such as Streptococcus pneumoniae, non-ty-
peableHaemophilus influenzae and Moraxella catarrhalis (Dohar
2003; Ruohola 2006), but Staphylococcus aureus and Pseudomonas
aeruginosa are also commonly found (Mandel 1994). Treatment
of this condition is aimed at eradicating the bacterial infection
and (topical) antibiotics are therefore predominantly prescribed.
Topical antibiotics may have several potential advantages over oral
antibiotics. First, antibiotic eardrops are delivered directly to the
site of infection resulting in a higher local concentration of an-
tibiotics. Second, antibiotic eardrops are (therefore) less likely to
cause antimicrobial resistance compared to oral antibiotics (Weber
2004). Third, antibiotic eardrops mainly have minor side effects,
such as local skin irritation or local allergy, while oral antibiotics
are associated with systemic side effects including diarrhoea, nau-
sea, rash, vomiting and potentially severe allergic reactions.
The use of (topical) corticosteroids as an adjunctive therapy to
antibiotic treatment is suggested to provide additional benefits in
resolving the ear discharge by inhibiting the inflammatory cascade
evoked in the middle ear as a result of the infection.
Since the middle ear infection that causes the ear discharge in pa-
tients with grommets may be self limiting over time, initial ob-
servation with or without daily suction (aural toilet) of the dis-
charging ear(s) may also be a good alternative to treatment with
antibiotics and/or corticosteroids.
Why it is important to do this review
The insertion of grommets is one of themost frequently performed
surgical procedures in children and ear discharge is a common se-
quela (Ah-Tye 2001; Cullen 2009; Kay 2001; van Dongen 2013).
The effectiveness of antibiotic eardrops with or without corticos-
teroids, systemic antibiotics and (saline) irrigation for the preven-
tion of postoperative ear discharge in children has recently been
reviewed (Syed 2013). The authors concluded that “if a surgeon
has a high rate of postoperative ear discharge in children then ei-
ther saline irrigation or antibiotic eardrops at the time of surgery
would significantly reduce that rate”. Still, even despite the use
of effective prophylactic interventions, many children with grom-
mets will develop ear discharge outside the immediate postoper-
ative period and it is unknown if any of these interventions are
also effective for this condition. Although most episodes of ear
discharge in patients with grommets are acute and transient, some
children develop chronic discharging ears, which may cause con-
siderable morbidity and hearing loss (Acuin 2004; van der Veen
2006). As such, it is important to optimise treatment for this con-
dition. A systematic review to assess the effectiveness of various
interventions for ear discharge in patients with grommets is there-
fore warranted.
O B J E C T I V E S
To assess the effectiveness and safety of various treatment strategies
in patients with grommets who developed ear discharge.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs), irrespective of the ran-
domisation method and blinding procedure used.
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Types of participants
Patients of any age with grommets (irrespective of type) who de-
veloped ear discharge. We will exclude those who had grommets
placed within the preceding two weeks.
Types of interventions
We will include all trials comparing the effectiveness and/or safety
of at least two of the following interventions and comparators:
1. Initial observation with or without daily suction (aural
toilet) of the discharging ear(s)
2. Oral antibiotics
3. Oral corticosteroids
4. Topical antibiotics with or without topical corticosteroids
5. Topical corticosteroids
6. Saline rinsing
7. Placebo (in the form of eardrops, oral suspension or tablets,
depending on the ’active’ intervention that is studied)
The main comparison of interest will be oral antibiotics versus
topical antibiotics with or without topical corticosteroids.
We will include RCTs reporting on combined interventions (e.g.
oral antibiotics plus topical antibiotics versus topical antibiotics
only) only if they allow a direct comparison between one of the
combined interventions and a control group and if the groups are
not treated differently except for the therapy that is studied.
Types of outcome measures
We will analyse the primary and secondary outcomes listed below
in this review, but we will not use these outcomes as a basis for
including or excluding studies.
Primary outcomes
1. Proportion of patients with resolution of ear discharge at
various time points (up to two weeks, two to four weeks and four
to 12 weeks)
2. Adverse events likely to be related to the use of study
medications (mainly ototoxicity, gastrointestinal symptoms and
allergic reactions)
3. Serious complications related to middle ear infection
including mastoiditis and intracranial complications
Secondary outcomes
1. Proportion of patients without ear pain and/or fever at two
time points (one to seven days and seven to 14 days)
2. Proportion of patients with tube extrusion
3. Proportion of patients with tube blockage
4. Health-related quality of life, either measured as disease-
specific quality of life using a validated instrument (e.g. Otitis
Media-6 questionnaire) or generic quality of life using a
validated instrument (e.g. EQ-5D; Infant Toddler Quality of
Life Questionnaire; Child Heath Questionnaire). We will analyse
disease-specific and generic health-related quality of life measures
separately
5. Total duration of the ear discharge episode after
randomisation
6. Proportion of patients with chronic ear discharge (duration
longer than four weeks)
7. Number of recurrent ear discharge episodes during follow-
up
8. Hearing levels as determined by audiometry
Search methods for identification of studies
TheCochrane Ear,Nose and ThroatDisorders GroupTrial Search
Co-ordinator will conduct systematic searches for randomised
controlled trials. There will be no language, publication year or
publication status restrictions. We may contact original authors
for clarification and further data if trial reports are unclear and we
will arrange translations of papers where necessary.
Electronic searches
Published, unpublished and ongoing studies will be identified by
searching the following databases from their inception:
• Cochrane Register of Studies Online (search to date);
• Ovid MEDLINE (1946 to date);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (1946 to date);
• PubMed (as a top up to searches in Ovid MEDLINE)
(1946 to date);
• Ovid EMBASE (1974 to date);
• EBSCO CINAHL (1982 to date);
• LILACS (search to date);
• KoreaMed (search to date);
• IndMed (search to date);
• PakMediNet (search to date);
• Web of Knowledge, Web of Science (1945 to date);
• ISRCTN (http://www.isrctn.com/) (search to date);
• ClinicalTrials.gov (www.clinicaltrials.gov) (search via the
Cochrane Register of Studies to date);
• ICTRP (search to date);
• Google Scholar (search to date);
• Google (search to date).
The subject strategies for databases will be modelled on the search
strategy designed for CENTRAL (Appendix 1). Where appropri-
ate, these will be combined with subject strategy adaptations of the
highly sensitive search strategy designed by The Cochrane Collab-
oration for identifying randomised controlled trials and controlled
clinical trials (as described in the Cochrane Handbook for System-
atic Reviews of Interventions Version 5.1.0, Box 6.4.b. (Handbook
2011)).
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Searching other resources
We will scan the reference lists of identified publications for ad-
ditional trials and contact trial authors if necessary. In addition,
the Trial Search Co-ordinator will search PubMed, TRIPdatabase,
The Cochrane Library and Google to retrieve existing systematic
reviews relevant to this systematic review, so that we can scan their
reference lists for additional trials.Wewill search for conference ab-
stracts using the Cochrane Ear, Nose and Throat Disorders Group
Trials Register and EMBASE.
Data collection and analysis
Selection of studies
Two review authors will independently screen the titles and ab-
stracts found by the searches and scan reference lists of relevant
studies and systematic reviews to assess potential relevance for full
review. The same review authors will independently review the full
text of potentially relevant studies against the pre-defined inclu-
sion and exclusion criteria. Any disagreements will be resolved by
discussion with a third review author.
Data extraction and management
Two review authors will independently extract data from the in-
cluded trials using a standardised data extraction form. We will
extract the following information from each trial:
1. Study characteristics: setting, design, method of data-
analysis.
2. Participants: study population, number of participants in
each group, patient characteristics including age, gender,
ethnicity, duration of ear discharge prior to enrollment, number
of discharging ears at baseline and main indication for tube
insertion.
3. Interventions: type of intervention and comparison used
including dosage, duration and route of administration.
4. Outcomes: primary and secondary outcomes recorded,
adverse events including adverse effects likely to be related to the
use of study medications and serious complications of middle ear
infection.
If a study provides more than one data point within the same time
period (e.g. data on the proportion of patients with resolution of
ear discharge at 5 and 10 days of follow-up), we will use the data
point with the shortest duration of follow-up. If a study reports
both parental and otoscopic observations, we will use the latter
as this is the considered the most objective method of diagnosing
resolution or persistence of middle ear infection (ear discharge) in
children.
Any disagreements in data extraction will be resolved by discussion
with a third review author.
Assessment of risk of bias in included studies
Two review authors will independently assess the methodological
quality of the included trials and any disagreements will be re-
solved by discussion with a third review author. We will perform
’Risk of bias’ assessment by using the ’Risk of bias’ tool described
in Chapter 8 of theCochrane Handbook for Systematic Reviews of
Interventions (Handbook 2011). We will judge the following do-
mains as high, low or unclear risk of bias:
• sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants and personnel (performance bias);
• blinding of outcome assessment (detection bias);
• incomplete outcome data (attrition bias);
• selective outcome reporting (reporting bias);
• other sources of bias.
We will present the results of the ’Risk of bias’ assessment in a
’Risk of bias’ graph and a ’Risk of bias’ summary.
Measures of treatment effect
Wewill express dichotomous outcomes as risk ratios (RRs) and risk
differences (RDs) with accompanying 95% confidence intervals
(CIs) and we will calculate the number needed to treat to benefit
(NNTB). We propose to express continuous outcome variables
either as mean differences (MDs), if reported on the same scale, or
as standardised mean differences (SMD), if different continuous
scales were used, with accompanying 95% CIs.
Unit of analysis issues
In the case of cluster-randomised trials, we will use analysis tech-
niques that take into account the effect of clustering, as described
in Chapter 16 of theCochrane Handbook for Systematic Reviews of
Interventions (Handbook 2011).
Dealing with missing data
One trial author will contact the corresponding trial authors of the
included trials to try to obtain additional information in case of
missing data. For continuous outcomes, we will calculate missing
statistics, such as standard deviations (SDs), from other available
statistics (e.g. P values) according the methods described in Chap-
ter 7 of theCochrane Handbook for Systematic Reviews of Interven-
tions (Handbook 2011).
Assessment of heterogeneity
We will assess the level of clinical diversity by reviewing the in-
cluded trials for potential differences between trials in study pop-
ulations, interventions or comparisons used and outcomes mea-
sured. We will assess statistical heterogeneity for each outcome
using the Chi² test, with a significance level set at P value < 0.10,
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and the I² statistic, with I² values of 50% or more suggesting sub-
stantial statistical heterogeneity (Handbook 2011).
Assessment of reporting biases
We will search the internet and ClinicalTrials.gov (http://
clinicaltrials.gov) for available study protocols to determine
whether outcomes reported in the included trials were pre-defined
and whether all outcomes listed in the study protocol were re-
ported in the publication. If there are sufficient trials, we propose
to assess reporting bias by using funnel plots.
Data synthesis
We will perform available case analyses, so using data for every
participant for whom the outcome was obtained, according to the
intention-to-treat (ITT) principle (i.e. analysing participants in
the groups to which they were originally allocated). We will per-
form meta-analyses in the absence of substantial clinical diversity.
We will use a fixed-effect meta-analysis where no statistical het-
erogeneity is present. We will use the more conservative random-
effects (DerSimonian and Laird) model if statistical heterogeneity
is detected but not resolved by subgroup or sensitivity analyses.
In primary analysis, we propose to pool data for the interven-
tions that are listed as a separate category under the Types of
interventions heading. As such, we will primarily combine data for
topical antibiotics only and topical antibiotics plus corticosteroids
(#4) if sufficient data are available. We will analyse separately data
from trials reporting on combined interventions (e.g. oral antibi-
otics plus topical antibiotics versus topical antibiotics only).
Subgroup analysis and investigation of heterogeneity
We propose to perform subgroup analysis for the following cate-
gories:
• age (children versus adults);
• duration of ear discharge prior to randomisation (four
weeks or less versus more than four weeks);
• number of discharging ears at baseline (unilateral versus
bilateral discharge);
• main indication for tube insertion (recurrent acute otitis
media versus persistent otitis media with effusion);
• type of topical treatment used (topical antibiotics only
versus topical antibiotics plus corticosteroids).
Sensitivity analysis
We propose to perform a sensitivity analysis in which only trials
judged as low risk of bias (based on a low risk in the key domains
affecting bias including allocation concealment and incomplete
outcome data) are included.
GRADE approach and ‘Summary of findings’
We will use the GRADE approach to rate the overall quality of
evidence for each outcome. We will rate the quality of evidence as
high, moderate, low or very low. We will rate evidence from RCTs
that do not have serious limitations as high quality. However, we
may downgrade the quality of evidence to moderate, low or very
low based on the following factors:
• study limitations (risk of bias);
• indirectness of evidence (directness of evidence);
• imprecision (precision of results);
• inconsistency (consistency of results);
• publication bias (existence of publication bias).
We will include a ’Summary of findings’ table for the main
comparison of interest (oral antibiotics versus topical antibiotics
with or without topical corticosteroids), which we will con-
struct according to the recommendations described in Chapter 10
of theCochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011).
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Middle Ear Ventilation] explode all trees
#2 grommet* or tubulation
#3 middle next ear near ventilat*
#4 (ventilat* near tube*) and ((otitis near media) or OME or ear)
#5 (tympanostomy or middle next ear or tympanic) near tube*
#6 ear* near insert* near tube*
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Cerebrospinal Fluid Otorrhea] explode all trees
#9 liquorrh* or liquorh* or otoliquorrh* or otoliquorh*
#10 suppurat* or pus or purulen* or discharg* or mucosal or otorrh* or otorh* or Mucopurulen* or wet or moist or weep*
#11 infect* or obstruct*
#12 (acute near otitis near media) or AOM or AOMT
#13 #8 or #9 or #10 or #11 or #12
#14 #7 and #13
#15 MeSH descriptor: [Middle Ear Ventilation] explode all trees and with qualifier(s): [Adverse effects - AE]
#16 #14 or #15
C O N T R I B U T I O N S O F A U T H O R S
Drafting of protocol: all authors
Screening search results: FJ, TMAvD
Extracting data: FJ, TMAvD
Assessing risk of bias: FJ, TMAvD
Entering data into RevMan: FJ, TMAvD
Carrying out analysis: FJ, TMAvD
Interpreting the analysis: all authors
General advice on the review: all authors
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